IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations.

Abstract

TPS5091Background: Tumors with biallelic CDK12 loss have been identified as a distinct subtype in metastatic castration resistant prostate cancer (mCRPC) and other cancer types. The CDK12 biallelic...